

## Scientific Publications

1. B.I. Joffe, I.M. Spitz, and G.E. Gale, Auto-immune haemolytic anaemia associated with  $\alpha$  methyl dopa therapy: a case report. *S.A. Med. J.* 41:907-909, 1967.
2. A.H. Rubenstein and I.M. Spitz, Role of the kidney in insulin metabolism and excretion. *Diabetes* 17:161-169, 1968.
3. I. Spector, B.I. Joffe, A.A. Zoutendyk, B. Fraser, I.M. Spitz, A. Dubb, M.C. Kew, G.C. Jones, and D. Hart, Studies on patients receiving  $\alpha$  methyl dopa. *S.A. Med. J.* 42:339- 342, 1968.
4. A.D. Wright, C. Lowy, R.T. Fraser, I.M. Spitz, A.H. Rubenstein, and I. Bersohn, Serum growth hormone and glucose intolerance in renal failure. *Lancet* ii:798-801, 1968.
5. I.M. Spitz, A.H. Rubenstein, I. Bersohn, and K.H. Bassler, Metabolism of xylitol in healthy subjects and patients with renal disease. *Metabolism* 19:24-34, 1970.
6. I.M. Spitz, A.H. Rubenstein, I. Bersohn, A.M. Lawrence, and L. Kirsteins, The effect of dialysis on the carbohydrate intolerance of chronic renal failure. *Horm. Met. Res.* 2:86-93, 1970.
7. I.M. Spitz, A.H. Rubenstein, I. Bersohn, and M. Van As, The blood sugar and serum insulin response to intravenous glucagon in chronic renal failure. *Proc. Soc. Exp. Biol. Med.* 134:142-145, 1970.
8. I.M. Spitz, A.H. Rubenstein, I. Bersohn, A.D. Wright, and C. Lowy, Urine insulin in renal disease. *J. Lab. Clin. Med.* 75:998-1005, 1970.
9. I.M. Spitz, I. Bersohn, A.H. Rubenstein, and M. Van As, The response of growth hormone to xylitol administration in man. *Am. J. Med. Sci* 260:224-229, 1970.
10. I.M. Spitz, A.H. Rubenstein, I. Bersohn, C. Abrahams, and C. Lowy, Carbohydrate metabolism in renal disease. *Quart. J. Med.* 39:201-226, 1970.
11. C. Lowy, A.D. Wright, R.T. Fraser, A.H. Rubenstein, and I.M. Spitz, Urine excretion of insulin and growth hormone in subjects with renal failure. *Acta Endocrinol.* 67:85-96, 1971.
12. A.H. Rubenstein, I. Spitz, and I. Bersohn, Metabolic and hormonal effects of xylitol in man. *Ernahrungswiss (suppl.)* 11:44-48, 1971.
13. I.M. Spitz, B. Gonen, and D. Rabinowitz, Growth hormone release in man revisited: Spontaneous vs stimulus-initiated tides, In: *Growth and Growth*

Hormone. Proceedings of the Second International Symposium, Milan. Excerpta Medica, Amsterdam, pp. 371-381, 1971 (Series no. 244).

14. D. Rabinowitz, I.M. Spitz, B. Bercovici, J. Bell, A. Laufer, and W.Z. Polishuk, Isolated deficiency of follicle-stimulating hormone. Clinical and laboratory features. *New Eng. J. Med.* 287:1313-1317, 1972.

15. I.M. Spitz, Metabolic abnormalities of renal disease, University of Witwatersrand (MD Thesis), 1972.

16. I.M. Spitz, B. Gonen, and D. Rabinowitz, Agnogenic and stimulus-initiated growth hormone release in man. A reappraisal and a multiple pool model of hormonal release. *Johns Hopkins Med. J.* 131:149-159, 1972.

17. J. Bell, I.M. Spitz, A. Perelman, S. Segal, Z. Palti, and D. Rabinowitz, Heterogeneity of gonadotropin responses to LHRH in hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.* 36:791-794, 1973.

18. H. Landau, S. Freier, I.M. Spitz, and D. Rabinowitz, Thyroid function tests in the first year of life. *Israel J. Med. Sci.* 9:929-931, 1973.

19. D. Rabinowitz, I.M. Spitz, B. Gonen, and E. Paran, Effects of single and multiple pulses of arginine on insulin release in man. *J. Clin. Endocrinol. Metab.* 36:901-905, 1973.

20. B. Schneider, R. Benveniste, I.M. Spitz, and D. Rabinowitz, Binding of human LH to particulate fraction of rat testis. Disparity in LH:IRP equipotency ratios in immuno and ligand assay. *Metabolism* 22:1225-1233, 1973.

21. H.C. Seftel, I.M. Spitz, I. Bersohn, A.R. Goldin, B.I. Joffe, A.H. Rubenstein, and B.E. Metzger, Metabolic features of Johannesburg Bantu with myocardial infarction. *S.A. Med. J.* 47:1571-1575, 1973.

22. I.M. Spitz, J. Bell, G. Arad, R. Benveniste, and D. Rabinowitz, Development of anti-human FSH antibody in a patient with isolated FSH deficiency. *J. Clin. Endocrinol. Metab.* 36:684-690, 1973.

23. T. Chajek, R. Tannenbaum, I.M. Spitz, and D. Rabinowitz, Comparative effects of insulin and proinsulin on lipolysis in isolated fat cells. *Israel J. Med. Sci.* 10:256-261, 1974.

24. I.M. Spitz, Y. Diamant, E. Rosen, J. Bell, M. Ben-David, W.Z. Polishuk, and D. Rabinowitz, Isolated gonadotropin deficiency. A heterogeneous syndrome. *New Eng. J. Med.* 290:10-15, 1974.

25. J. Bell, R. Benveniste, I.M. Spitz, and D. Rabinowitz, Isolated deficiency of follicle stimulating hormone: Further studies. *J. Clin. Endocrinol. Metab.* 40:790-794, 1975.
26. R. Benveniste, L.A. Frohman, J. Bell, I.M. Spitz, and D. Rabinowitz, Alpha subunit of glycoprotein hormone: presence in peripheral serum after LHRH. *European J. Clin. Invest.* 5:123-131, 1975.
27. W.Z. Polishuk, S. Yarkoni, M. Ben-David, and I.M. Spitz, Hyperprolactinemic amenorrhea and sterility treated with bromocriptine. *J. Isr. Med. Assoc. (Harefuah)* 89:500-503, 1975.
28. D. Rabinowitz, M.M. Cohen, A. Rosenmann, S. Segal, J. Bell, A. Rosler, and I.M. Spitz, Chromatin-positive Klinefelter's Syndrome with undetectable peripheral FSH levels. *Am. J. Med.* 59:584-590, 1975.
29. D. Rabinowitz and I.M. Spitz, Isolated gonadotropin deficiency and related disorders. *Israel J. Med. Sci.* 11:1011-1078, 1975.
30. Z. Schumert, I.M. Spitz, Y. Diamant, W.Z. Polishuk, and D. Rabinowitz, Elevation of serum testosterone in ovarian hyperstimulation syndrome. *J. Clin. Endocrinol. Metab.* 40:889-892, 1975.
31. J. Bernheim, M. Shapira, I.M. Spitz, J. Shapiro, and D. LeRoith, Elevation des taux de parathormone (PTH) serique en cas d'hyperprolactinemie. *La Nouv. Pres. Med.* 6:41-43, 1977.
32. D. Rabinowitz, R. Benveniste, and I.M. Spitz, Isolated deficiency of follicle stimulating hormone, In: *Proceedings of the V International Congress of Endocrinology.* (V.H.T. James, eds.), *Excerpta Medica International Congress Series no. 403, Hamburg, vol. 2 pp. 340-344, 1977.*
33. J. Schenker, N. Laufer, E. Rosen, and I.M. Spitz, Hormonal response to exogenous luteinizing hormone-releasing hormone and thyrotropin-releasing hormone in pregnancy and puerperium. *Israel J. Med. Sci.* 13:482-487, 1977.
34. I.M. Spitz, U. Almaliach, E. Rosen, W. Polishuk, and D. Rabinowitz, Dissociation of prolactin responsiveness to TRH and chlorpromazine in women with isolated gonadotropin deficiency. *J. Clin. Endocrinol. Metab.* 45:1173-1178, 1977.
35. I.M. Spitz, H. Landau, U. Almaliach, E. Rosen, N. Brautbar, and A. Russell, Diminished prolactin reserve. A case report. *J. Clin. Endocrinol. Metab.* 45:412-418, 1977.
36. I.M. Spitz, E. Rosen, N. Ben-Aderet, W. Polishuk, H. Jaffe, and B. Bercovici, Isolated hypogonadotropic hypogonadism: Induction of ovulation with exogenous gonadotropins. *Fertil. Steril.* 28:535-540, 1977.

37. S. Yarkoni, W.Z. Polishuk, I.M. Spitz, and M. Ben-David, Inhibitory effect of hyperprolactinemia on induction of ovulation by gonadotropins. *Fertil. Steril.* 28:772-774, 1977.
38. H. Landau, I. Adin, and I.M. Spitz, Pituitary insufficiency following head injury. *Israel J. Med. Sci.* 14:785-789, 1978.
39. H. Landau, E. Lasch, I.M. Spitz, I. Abu Amara, and A. Russell, Hypothalamic-pituitary axis in total lipodystrophy. *Monog. Hum. Genet.* 10:188-191, 1978.
40. H. Landau, I.M. Spitz, G. Cividalli, and E.A. Rachmilewitz, Gonadotrophin, thyrotrophin and prolactin reserve in  $\beta$  thalassemia. *Clin. Endocrinol.* 9:163-173, 1978.
41. D. Rabinowitz, I.M. Spitz, and R. Benveniste, Isolated gonadotropin deficiency, In: *Endocrine causes of menstrual disorders.* (J.R. Givens, eds.), Year Book Medical Publishers Inc., pp. 181-190, 1978.
42. I.M. Spitz, N. Laufer, J. Schenker, and E. Rosen, The hormonal response to the administration of LH-releasing hormone and TSH-releasing hormone in pregnancy and the puerperium, In: *Hypothalamic Hormones - Chemistry, Physiology, and Clinical Applications.* (D. Gupta and W. Voelter, eds.), Verlag Chemie, Weinheim, pp. 599-608, 1978.
43. I.M. Spitz, E. Rosen, J. Schenker, and W.Z. Polishuk, The effect of estrogen administration on the prolactin response to chlorpromazine in isolated gonadotropin deficiency and ovarian failure, In: *Hypothalamic Hormones - Chemistry, Physiology, and Clinical Applications.* (D. Gupta and W. Voelter, eds.), Verlag Chemie, Weinheim, pp. 639-648, 1978.
44. I.M. Spitz, Z. Schumert, J. Steiner, E. Rosen, S. Segal, A. Slonim, and D. Rabinowitz, Induction of spermatogenesis in hypogonadotrophic hypogonadism. *Postgrad Med. J.* 54:694-697, 1978.
45. S. Yarkoni, I.M. Spitz, M. Ben-David, and W.Z. Polishuk, Failure of bromocriptine to suppress prolactin in majepetil-induced hyperprolactinemia. *Acta Eur. Fertil.* 9:185-188, 1978.
46. R. Goldberg, N. Conforti, and I.M. Spitz, Analgesia induced by intraventricular administration of methionine enkephalin in rats. *Neuroendocrinol. Letters* 1:75-80, 1979.
47. D. LeRoith, M. Shapiro, A. Gutman, and I.M. Spitz, Hypothalamic pituitary function in Cushing's disease. *J. Endocrinol. Invest.* 2:379-383, 1979.

48. D. LeRoith, M. Shapiro, K. Jabotinsky, and I.M. Spitz, Prolactin nonresponsiveness to arginine in diabetes mellitus. *Horm. Metab. Res.* 11:583-584, 1979.
49. D. LeRoith, G. Danowitz, S. Trestian, and I.M. Spitz, Dissociation of prolactin response to TRH and metoclopramide in chronic renal failure. *J. Clin. Endocrinol. Metab.* 49:815-817, 1979.
50. R. Luboshitzky, E. Rosen, S. Trestian, and I.M. Spitz, Hyperprolactinemia and hypogonadism in men: response to exogenous gonadotrophins. *Clin. Endocrinol.* 11:217-223, 1979.
51. R. Luboshitzky, J.D. Sobel, A. Kurtzbaum, O.S. Better, and I.M. Spitz, Hypopituitarism with water intoxication and coma. Favorable outcome following early treatment. *J. Endocrinol. Invest.* 2:423-426, 1979.
52. I.M. Spitz, B. Gonen, R. Luboshitzky, E. Rosen, and O. Shemesh, The prolactin response to repeated intravenous stimuli. *Horm. Metab. Res.* 11:319-320, 1979.
53. I.M. Spitz, S. Trestian, H. Cohen, N. Arnon, and D. LeRoith, Failure of metoclopramide to influence LH, FSH and TSH secretion or their response to releasing hormones. *Acta Endocrinol.* 92:640-647, 1979.
54. I.M. Spitz, E. Zylber, H. Cohen, U. Almaliach, and D. LeRoith, Impaired prolactin response to TRH in isolated gonadotropin deficiency and exaggerated response in primary testicular failure. *J. Clin. Endocrinol. Metab.* 48:941- 945, 1979.
55. I.M. Spitz, E. Zylber, J. Jersky, and D. LeRoith, Atropine suppression of basal and metoclopramide-induced human pancreatic polypeptide secretion in man. *Metabolism* 28:527-530, 1979.
56. E. Zylber, H. Gershman, and I.M. Spitz, The prolactin response to TRH and metoclopramide in the castrated rat. *Neuroendocrinol. Letters* 1:81-87, 1979.
57. E. Zylber, D. LeRoith, J. Jersky, and I.M. Spitz, The effect of metoclopramide on human pancreatic polypeptide secretion in normal subjects and maturity onset diabetics, In: *Pediatric and Adolescent Endocrinology: Nutrition and the Diabetic Child.* (Z. Laron and M. Karp, eds.), S. Karger, Basel, vol. 7 pp. 356-360, 1979.
58. D. LeRoith, G. Danovitz, S. Trestian, and I.M. Spitz, Dissociation of pituitary glycoprotein response to releasing hormones in chronic renal failure. *Acta Endocrinol.* 93:277-282, 1980.

59. D. LeRoith, Y. Farkash, J. Bar-Ziev, and I.M. Spitz, Hypothalamic-pituitary function in the Bardet-Biedl syndrome. *Israel J. Med. Sci.* 16:514-518, 1980.
60. D. LeRoith, M. Shapiro, R. Luboshitzky, and I.M. Spitz, The hypothalamic pituitary axis in diabetes mellitus. *Horm. Metab. Res.* 12:608-611, 1980.
61. D. LeRoith, I.M. Spitz, R. Ebert, Y. Liel, S. Odes, and W. Creutzfeldt, Acid-induced GIP secretion in man. *J. Clin. Endocrinol. Metab.* 51:1385-1389, 1980.
62. M.S. Shapiro, J. Bernheim, A. Gutman, I. Arber, and I.M. Spitz, Multiple abnormalities of anterior pituitary hormone secretion in association with pseudohypoparathyroidism. *J. Clin. Endocrinol. Metab.* 51:483-487, 1980.
63. O. Shemesh, R. Luboshitzky, B. Gonen, E. Rosen, and I.M. Spitz, Dissociation of prolactin and TSH responses after repeated pulses of TRH. *J. Israel Med. Assoc. (Harephua)* 98:333-335, 1980.
64. I.M. Spitz, D. Barzilai, and R. Luboshitzky, Diminished prolactin reserve in acromegaly. *Metabolism* 29:880-884, 1980.
65. I.M. Spitz, D. LeRoith, Y. Livshin, E. Zylber-Haran, S. Trestian, N. Laufer, M. Ron, Z. Palti, and J. Schenker, Exaggerated prolactin response to thyrotropin-releasing hormone and metoclopramide in primary testicular failure. *Fert. Steril.* 34:573-580, 1980.
66. I.M. Spitz, D. LeRoith, S. Trestian, R. Ebert, and W. Creutzfeldt, Effect of acid on GIP secretion in man. *Front. Horm. Res.* 70:173-180, 1980.
67. D. LeRoith, Y. Liel, M. Caine, and I.M. Spitz, The prolactin response to thyrotropin-releasing hormone is intact in the human castrate. *Acta Endocrinol.* 96:163-167, 1981.
68. D. LeRoith, Y. Liel, J. Sack, Y. Livshin, N. Laufer, J. Schenker, and I.M. Spitz, The TSH response to TRH is exaggerated in primary testicular failure and intact in the male castrate. *Acta Endocrinol.* 97:103-108, 1981.
69. D. LeRoith, G. Potashnik, J. Dunn, and I.M. Spitz, The exaggerated prolactin response to thyrotropin-releasing hormone and metoclopramide in 1,2-dibromo-3-chloropropane-induced azoospermia. *J. Clin. Endocrinol. Metab.* 52:38-41, 1981.
70. M. Ron, I. Spitz, R. Adatto-Levi, A. Adoni, and Z. Palti, Serum prolactin levels in spermatic, renal, and cubital veins during spermatic vein ligation. *Int. J. Fertil.* 26:138-140, 1981.

71. S. Shilo, Y. Livshin, J. Sheskin, and I.M. Spitz, Gonadal function in lepromatous leprosy. *Lepr. Rev.* 52:127-134, 1981.
72. I.M. Spitz, Decreased basal and stimulated prolactin levels in isolated gonadotropin deficiency: A manifestation of estrogen deficiency. Third International Congress on Prolactin, Athens, Greece. *Neuroendocrinol. Letters* 3:324, 1981.
73. I.M. Spitz, Y. Halperin, S. Shilo, D. LeRoith, E. Zylber-Haran, Y. Livshin, N. Laufer, and J. Schenker, Clomiphene attenuates the exaggerated prolactin response to thyrotropin-releasing hormone and metoclopramide occurring in primary testicular failure. *J. Clin. Endocrinol. Metab.* 52:289-293, 1981.
74. I.M. Spitz, Y. Halperin, E. Zylber-Haran, S. Shilo, D. LeRoith, Y. Liel, J. Livshin, N. Laufer, and J. Schenker, Prolactin response to metoclopramide and chlorpromazine in primary testicular failure and isolated gonadotrophin deficiency. *Clin. Endocrinol.* 14:375-380, 1981.
75. I.M. Spitz, D. LeRoith, H. Hirsch, P. Carayon, F. Pekonen, Y. Liel, R. Sobel, Z. Chorer, and B. Weintraub, Increased high-molecular-weight thyrotropin with impaired biologic activity in a euthyroid man. *N. Engl. J. Med.* 304:278-282, 1981.
76. I.M. Spitz, E. Zylber-Haran, and S. Trestian, Limitations of chlorpromazine in the assessment of prolactin reserve in treated subjects with isolated gonadotropin deficiency. *Neuroendocrinol. Letters* 3:267-276, 1981.
77. E.A. Zylber-Haran, H. Gershman, and I.M. Spitz, The prolactin response to metoclopramide in the castrated male rat. *Biol. Reprod.* 25:1-5, 1981.
78. E.A. Zylber-Haran, H. Gershman, and I.M. Spitz, Effects of testosterone, dihydrotestosterone and estradiol on the impaired prolactin response to metoclopramide in the castrated rat. *Biol. Reprod.* 25:6-14, 1981.
79. R. Goldberg, N. Conforti, and I.M. Spitz, The effect of methionine enkephalin on prolactin and luteinizing hormone levels in intact and castrated rats. *Horm. Metab. Res.* 14:89-92, 1982.
80. D. Hochner-Celnikier, E.A. Zylber-Haran, S. Shilo, Z. Palti, and I.M. Spitz, The prolactin response to thyrotropin releasing hormone is increased in primary ovarian failure. *Obstet. Gynecol.* 59:280-284, 1982.
81. M. Shapiro, A. Gutman, G. Schey, I. Bruderman, R. Taragan, and I.M. Spitz, Asthma as the primary manifestation of selective ACTH deficiency associated with latent primary hypothyroidism. *Harefuah* 103:104-105, 1982.

82. S. Shilo, Y. Livshin, E. Zylber-Haran, J. Sheskin, and I.M. Spitz, Gonadotropin, prolactin and thyrotropin secretion in lepromatous leprosy. *J. Androl.* 3:320-325, 1982.

83. I.M. Spitz, E. Kerem, E.A. Zylber-Haran, S. Shilo, N. Laufer, Y. Livshin, and J. Schenker, Clomiphene citrate does not modify the exaggerated thyrotropin response to thyrotropin-releasing hormone occurring in primary testicular failure. *Clin. Endocrinol.* 16:139-145, 1982.

84. I.M. Spitz, H. Landau, V. Gross, S. Trestian, Z. Palti, and E. Rachmilewitz, Prolactin responsiveness to TRH and metoclopramide in thalassaemia. *Clin. Endocrinol.* 16:275- 282, 1982.

85. I.M. Spitz, P. Lavie, N. Calderon, C.R. Gordon, A. Oksenberg, M. Ron, N. Laufer, Y. Livshin, and J. Schenker, Dissociation between sleep-related and TRH-induced prolactin secretion in seminiferous tubule failure. *Metabolism* 31:10-13, 1982.

86. I.M. Spitz, B.H. Novis, R. Ebert, S. Trestian, D. LeRoith, and W. Creutzfeldt, Betazole-induced GIP secretion is not mediated by gastric HCl. *Metabolism* 31:380-382, 1982.

87. I.M. Spitz, E.A. Zylber-Haran, S. Trestian, Y. Dickstein, Z. Palti, and J. Schenker, The decreased basal and stimulated prolactin levels in isolated gonadotropin deficiency: A consequence of the low oestrogen state. *Clin. Endocrinol.* 16:423-432, 1982.

88. E.A. Zylber-Haran, H. Gershman, E. Rosenmann, and I.M. Spitz, Gonadotrophin, testosterone and prolactin interrelationships in cadmium-treated rats. *J. Endocrinol.* 92:123-130, 1982.

89. D. Ayalon, N. Eckstein, S. Avidan, A. Eshel, M. L'Hermite, A. Caufriez, I. Spitz, and E. Zylber-Haran, Dopaminergic regulation of prolactin secretion in the hyperprolactinemic syndrome. *Gynecol. Obstet. Invest.* 16:97-106, 1983.

90. I.M. Spitz, N. Algur, E. Zylber-Haran, N.A. Musto, and C.W. Bardin, Gonadotropin-prolactin interactions in the  $H^{1c}/+$  rat: A longitudinal study. *Biol. Reprod.* 28:1071-1077, 1983.

91. I.M. Spitz, M. Haas, S. Trestian, E. Zylber-Haran, and S. Shilo, The interrelationships between PRL and TSH secretion following dopaminergic blockade in patients with mild hyperprolactinemia without any demonstrable pituitary tumor. *Clin. Endocrinol.* 19:285-294, 1983.

92. I.M. Spitz, H.J. Hirsch, and S. Trestian, The role of thyrotropin releasing hormone in the diagnosis of isolated gonadotropin deficiency. *J. Steroid Biochem.* 19:901-906, 1983.



93. I.M. Spitz, H.J. Hirsch, and S. Trestian, The prolactin response to thyrotropin releasing hormone differentiates isolated gonadotropin deficiency from delayed puberty. *New Engl. J. Med.* 308:575-579, 1983.

94. I.M. Spitz, B. Levitt, E. Zylber-Haran, M. Haas, and Y. Livshin, The dissociation of the exaggerated prolactin and thyrotropin responses in seminiferous tubule failure following the administration of a double pulse of thyrotropin releasing hormone. *J. Endocrinol. Invest.* 6:273-276, 1983.

95. I.M. Spitz, E.A. Zylber-Haran, and S. Trestian, The thyrotropin (TSH) profile in isolated gonadotropin deficiency: A model to evaluate the effect of sex steroids on TSH secretion. *J. Clin. Endocrinol. Metab.* 57:415-420, 1983.

96. I.M. Spitz, E.A. Zylber-Haran, and S. Trestian, Relationship of prolactin secretion to testicular function, In: *Prolactin and Prolactinomas.* (G. Tolis, C. Stefanis, T. Mountokalakis and F. Labrie, eds.), Raven Press, New York, pp. 179-191, 1983.

97. K.E. Anderson, I.M. Spitz, S. Sassa, C.W. Bardin, and A. Kappas, Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. *New Engl. J. Med.* 311:643-645, 1984.

98. B.I. Joffe, I.M. Spitz, H.J. Hirsch, R. Shires, I. Segal, and H.C. Seftel, Hormonal profile after insulin-induced hypoglycemia in chronic calcific pancreatitis. Pancreatic, pituitary and adrenal responses. *Horm. Metab. Res.* 16 (Suppl.):134-137, 1984.

99. H. Landau, V. Gross, I. Dagan, Z. Palti, E.A. Rachmilewitz, and I.M. Spitz, Growth and sexual development before and after sex steroid therapy in patients with thalassemia major. *Arch. Int. Med.* 144:2341-2346, 1984.

100. I.M. Spitz, H.J. Hirsch, H. Landau, E. Zylber-Haran, V. Gross, and E.A. Rachmilewitz, TSH secretion in thalassemia. *J. Endocrinol. Invest.* 7:495-499, 1984.

101. I.M. Spitz, E.J. Margalioth, Y. Yeager, Y. Livshin, E. Zylber-Haran, and S. Shilo, Effect of non aromatizable androgens on LHRH and TRH responses in primary testicular failure. *Horm. Metab. Res.* 16:492-496, 1984.

102. I.M. Spitz, M. Sheinfeld, B. Glasser, and H.J. Hirsch, Hyperthyroidism due to inappropriate TSH secretion with associated hyperprolactinaemia: a case report and review of the literature. *Postgrad. Med. J.* 60:328-335, 1984.

103. G.P. Chrousos, L. Nieman, D. Healy, I. Spitz, G. Hodgen, C.W. Bardin, G.B. Cutler Jr, H.M. Schulte, G.R. Merriam, D.D. Brandon, and D.L. Loriaux, Antigluocorticoids: General aspects and clinical implications, In: *Aspects of*

Glucocorticoid Research and Therapy. (H.L. Fehm, K. Graupe, and J. Kobberling, eds.), Perimed Fachbuch, Verlagsgesellschaft, Erlangen, pp. 54-71, 1985.

104. H.B. Croxatto, I.M. Spitz, A.M. Salvatierra, and C.W. Bardin, The demonstration of the antiprogestin effects of RU486 when administered to the human during hCG-stimulated pseudopregnancy, In: The Antiprogestin Steroid RU 486 and Human Fertility Control. (E.E. Baulieu and S. Segal, eds.), Plenum Press, New York and London, pp. 263-269, 1985.

105. L.K. Nieman, G.P. Chrousos, C. Kellner, I.M. Spitz, B.C. Nisula, G.B. Cutler Jr, G.R. Merriam, C.W. Bardin, and D.L. Loriaux, Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. 61:536-540, 1985.

106. L.K. Nieman, G.P. Chrousos, C. Kellner, I.M. Spitz, B.C. Nisula, G.B. Cutler Jr, G.R. Merriam, C.W. Bardin, and D.L. Loriaux, Use of the glucocorticoid antagonist RU 486 in the treatment of Cushing's syndrome, In: The Antiprogestin Steroid RU 486 and Human Fertility Control. (E.E. Baulieu and S. Segal, eds.), Plenum Press, New York and London, pp. 339-345, 1985.

107. L.K. Nieman, D.L. Healy, I.M. Spitz, G.R. Merriam, C.W. Bardin, D.L. Loriaux, and G.P. Chrousos, Use of single doses of the antiprogestin steroid RU 486 for induction of menstruation in normal women, In: The Antiprogestin Steroid RU 486 and Human Fertility Control. (E.E. Baulieu and S. Segal, eds.), Plenum Press, New York and London, pp. 279-283, 1985.

108. D. Shoupe, D.R. Mishell Jr, M. Lacarra, E. Gutierrez, P. Lahteenmaki, and I.M. Spitz, Endocrinologic effects of the antiprogestin RU 486 in the luteal phase of normal women, In: The Antiprogestin Steroid RU 486 and Human Fertility Control. (E.E. Baulieu and S.J. Segal, eds.), Plenum Press, New York and London, pp. 285-293, 1985.

109. R. Sitruk-Ware, L. Billaud, I. Mowszowicz, H. Yaneva, P. Mauvais-Jarvis, C.W. Bardin, and I.M. Spitz, The use of RU 486 as an abortifacient in early pregnancy, In: The Antiprogestin Steroid RU 486 and Human Fertility Control. (E.E. Baulieu and S.J. Segal, eds.), Plenum Press, New York and London, pp. 243-248, 1985.

110. I.M. Spitz, Hyperprolactinemia of undefined etiology, In: Current Therapy in Endocrinology and Metabolism. (D.T. Krieger and C.W. Bardin, eds.), B.C. Decker, Inc. and C.V. Mosby Co., St. Louis, Toronto, London Philadelphia, pp. P34-P38, 1985.

111. I.M. Spitz, G.L. Gunsalus, J.P. Mather, R. Thau, and C.W. Bardin, The effects of the indazole carboxylic acid derivative, tolnidamine, on testicular function: I. Early changes in androgen binding protein secretion in the rat. J. Androl. 6:171-178, 1985.

112. I.M. Spitz, C.E. Wade, D.T. Krieger, P. Lahteenmaki, and C.W. Bardin, Effect of RU 486 in the dog, In: *The Antiprogestin Steroid RU 486 and Human Fertility Control.* (E.E. Baulieu and S.J. Segal, eds.), Plenum Press, New York and London, pp. 315-329, 1985.
113. K.E. Anderson, I.M. Spitz, S. Sassa, C.W. Bardin, and A. Kappas, Intranasal luteinizing hormone-releasing hormone agonist for prevention of cyclical attacks of acute intermittent porphyria, In: *Porphyryns and Porphyria*, INSERM vol. 134. (Y. Nordmann, eds.), John Libbey Eurotext Ltd., Paris, pp. 225-231, 1986.
114. A. Hershlag, I.M. Spitz, D. Hochner-Celnikier, Y. Haskel, D.Z. Lernau, S. Nissan, A. Rosenmann, and E. Rosenmann, Persistent Mullerian structures in an infertile male. *Urology* 28:138-141, 1986.
115. H.J. Hirsch, S. Shilo, and I.M. Spitz, Evolution of hypothyroidism in familial goiter due to deiodinase deficiency: Report of a family and review of the literature. *Postgrad. M. J.* 62:477-480, 1986.
116. P. Scorza Barcellona, V. Cioli, C. De Martino, C.W. Bardin, and I.M. Spitz, Tolnidamine in male contraception: A survey of preclinical data, In: *Male Contraception: Advances and Future Prospects.* (G.I. Zatuchni, A. Goldsmith, J.M. Spieler, J.J. Sciarra, eds.), Harper & Row, Philadelphia, pp. 237-251, 1986.
117. D. Shoupe, D.R. Mishell, P.F. Brenner, and I.M. Spitz, Pregnancy termination with a high and medium dosage regimen of RU 486. *Contraception* 33:455-461, 1986.
118. I.M. Spitz and C.W. Bardin, Antiprogestins: Prospects for a once-a-month pill. *Fam. Plann. Pros.* 17:260-262, 1986.
119. M. Bifulco, I.M. Spitz, H.J. Hirsch, Z. Shorer, and S.M. Aloj, High-molecular-weight thyrotropin revisited. *New Engl. J. Med.* 316:1609-1610, 1987.
120. H.B. Croxatto, A.M. Salvatierra, C. Romero, and I.M. Spitz, Late luteal phase administration of RU 486 for three successive cycles does not disrupt bleeding patterns or ovulation. *J. Clin. Endocrinol. Metab.* 65:1272-1277, 1987.
121. O. Heikinheimo, K. Kontula, H. Croxatto, I. Spitz, T. Luukkainen, and P. Lahteenmaki, Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. *J. Steroid Biochem.* 26:279-286, 1987.

122. D. Kenigsberg, J. Porte, M. Hull, and I.M. Spitz, Medical treatment of residual ectopic pregnancy: RU 486 and methotrexate. *Fertil. Steril.* 47:702-703, 1987.
123. P. Lahteenmaki, O. Heikinheimo, H. Croxatto, I.M. Spitz, D. Shoupe, L. Birgersson, and T. Luukkainen, Pharmacokinetics and metabolism of RU 486. *J. Steroid Biochem.* 27:859-863, 1987.
124. D.R. Mishell, Jr., D. Shoupe, D.F. Brenner, M. Lacarra, J. Horenstein, P. Lahteenmaki, and I.M. Spitz, Termination of early gestation with the anti-progestin steroid RU 486: Medium versus low dose. *Contraception* 35:307-321, 1987.
125. L.K. Nieman, T.M. Choate, G.P. Chrousos, D.L. Healy, M. Morin, D. Renquist, G.R. Merriam, I.M. Spitz, C.W. Bardin, E.-E. Baulieu, and D.L. Loriaux, The progesterone antagonist RU 486: A potential new contraceptive agent. *New Engl. J. Med.* 316:187-191, 1987.
126. D. Shoupe, D.R. Mishell, Jr., P. Lahteenmaki, O. Heikinheimo, L. Birgersson, H. Madkour, and I.M. Spitz, Effects of the antiprogesterone RU 486 in normal women. I: Single dose administration in the midluteal phase. *Am. J. Obstet. Gynecol.* 157:1415-1420, 1987.
127. D. Shoupe, D.R. Mishell, Jr., M.A. Page, H. Madkour, I.M. Spitz, and R.A. Lobo, Effects of an antiprogesterone RU 486 in normal women. II: Administration in the late follicular phase. *Am. J. Obstet. Gynecol.* 157:1421-1426, 1987.
128. H.J. Hirsch, J. Golan, N. Ben-Hur, and I.M. Spitz, Isolated gonadotropin deficiency in a boy with hypotelorism and median facial defect. *Eur. J. Pediatr.* 147:656-657, 1988.
129. J. Marraoui, S. Dubourdiou, N. Lahlou, M. Roger, S. Brailly, I.M. Spitz, R. Frydman, B. Charbonnel, S. Delivet, G. Schaison, and P. Bouchard, Antagonistes de la GnRH en medecine de la reproduction: Resultats cliniques abtenus avec le Nal-Glu. *Contraception, Fertil. Sex.* 16:911-914, 1988.
130. I.M. Spitz, Clinical studies with RU 486, In: *Beijing International Fertility Regulation Symposium*. State Family Planning Commission of China, Beijing, pp. 287-298, 1988.
131. C.E. Wade, I.M. Spitz, P. Lahteenmaki, O. Heikinheimo, D.T. Krieger, and C.W. Bardin, Effects of the antigluocorticoid RU 486 on adrenal function in dogs. *J. Clin. Endocrinol. Metabol.* 66:473-479, 1988.
132. P.W. Concannon, L. Dillingham, and I.M. Spitz, Effects of the antiprogesterone RU 486 on progesterone-dependent uterine development and

bioassay of progestational activity in estrogen- primed immature female dogs. *Acta Endocrinologia* 118:389-398, 1989.

133. H.B. Croxatto, A.M. Salvatierra, H.D. Croxatto, and I.M. Spitz, Variable effects of RU 486 on endometrium maintenance in the luteal phase extended by exogenous hCG. *Clin. Endocrinol.* 31:15-23, 1989.

134. V. Rossi, C.Y. Cheng, G.L. Gunsalus, C.W. Bardin, and I.M. Spitz, The differential effects of the indazole-carboxylic acid derivative, tolnidamine, on Sertoli cell protein secretion. *J. Androl.* 10:466-471, 1989.

135. I.M. Spitz and C.W. Bardin, Progesterone antagonists on the horizon. *Clin. Obstet. Gynecol.* 32:403-413, 1989.

136. I.M. Spitz, D. Shoupe, R. Sitruk-Ware, and D.R. Mishell, Jr., Response to the antiprogestagen RU 486 (mifepristone) during early pregnancy and the menstrual cycle in women. *J. Reprod. Fertil. Suppl.* 37:253-260, 1989.

137. K.E. Anderson, I.M. Spitz, C.W. Bardin, and A. Kappas, A gonadotropin-releasing hormone analogue prevents cyclical attacks of porphyria. *Arch. Int. Med.* 150:1469-1474, 1990.

138. R.H. Asch, L.N. Weckstein, J.P. Balmaceda, F. Rojas, I.M. Spitz, and Y. Tadir, Non-surgical expulsion of non-viable early pregnancy: A new application of RU 486. *Human Reprod.* 5:481-483, 1990.

139. P. Bouchard, A. Caraty, D. Medalie, M.R. Massai, S. Dubourdieu, B. Charbonnel, R. Frydman, Y.Y. Tsong, G. Schaison, and I.M. Spitz, Mechanisms of action and clinical uses of GnRH antagonists in women, In: *Recent Progress on GnRH and Gonadal Peptides.* (P. Bouchard, F. Haour, P. Franchimont, and B. Schatz, eds.), Elsevier, Paris, pp. 209-219, 1990.

140. P. Bouchard, S. Hajri, N. Lahlou, M. Roger, S. Brailly, S. Dubourdieu, R. Frydman, B. Charbonnel, S. Delivet, G. Schaison, Y.Y. Tsong, and I.M. Spitz, Precocious puberty, contraception and safety issues: Clinical studies with the GnRH antagonist (Nal-Glu), In: *GnRH Analogues in Cancer and Human Reproduction, Vol. IV.* (B. Vickery and B. Lunenfeld, eds.), pp. 133-140, 1990.

141. A. Caraty, A. Locatelli, B. Delaleu, I.M. Spitz, B. Schatz, and P. Bouchard, Gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists do not alter endogenous GnRH secretion in short-term castrated rams. *Endocrinology* 127:2523-2529, 1990.

142. N. Lahlou, S. Delivet, C.W. Bardin, M. Roger, I.M. Spitz, and P. Bouchard, Changes in gonadotropin and  $\alpha$ -subunit secretion after a single administration of gonadotropin releasing hormone antagonist in adult males. *Fertil. Steril.* 53:898-905, 1990.

143. V. Rossi, L. Caricato, L. Jovicevic, C. De Martino, I.M. Spitz, and C.Y. Cheng, The use of rat testibumin to monitor the effect of tolnidamine on testicular damage. *Med. Sci. Res.* 18:559-560, 1990.
144. V. Rossi, C.Y. Cheng, G.L. Gunsalus, C.W. Bardin, and I.M. Spitz, Age-dependent differential secretion of two secretory proteins from Sertoli cells of rats: ABP and testibumin. *Mol. Androl.* 11:85-96, 1990.
145. D. Shoupe, D.R. Mishell, G. Fossum, B.L. Bopp, I.M. Spitz, and R.A. Lobo, Antiprogestin treatment decreases midluteal luteinizing hormone pulse amplitude and primarily exerts a pituitary inhibition. *Am. J. Obstet. Gynecol* 163:1982-1985, 1990.
146. R. Sitruk-Ware, J.-C. Thalabard, T.L. De Plunkett, F. Lewin, S. Epelboin, I. Mowszowicz, H. Yaneva, M. Tournaire, J. Chavinie, P. Mauvais-Jarvis, and I.M. Spitz, RU 486 (Mifepristone) as an abortifacient in early pregnancy - Clinical and pathological findings; predictive factors for efficacy. *Contraception* 41:221-243, 1990.
147. R. Sitruk-Ware, H. Yaneva, and I.M. Spitz, Antiprogestins and endometrial morphology, In: *Contraception and Mechanisms of Endometrial Bleeding.* (I.S. Fraser, J.R. Newton, and V. Odland, eds.), Cambridge University Press, Cambridge, pp. 325-336, 1990.
148. S. Dubourdieu, B. Charbonnel, M.R. Massai, J. Marraoui, I.M. Spitz, and P. Bouchard, Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration. *Fertil. Steril.* 56:440-445, 1991.
149. R. Frydman, J. Taieb, C. Cornel, I.M. Spitz, D. deZiegler, and P. Bouchard, Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. *Fertil. Steril.* 56:923-927, 1991.
150. S.M. Grunberg, M.H. Weiss, I.M. Spitz, J. Ahmadi, A. Sadun, C.A. Russell, L. Lucci, and L.L. Stevenson, Treatment of unresectable meningioma with the antiprogestone agent mifepristone. *J. Neurosurg.* 74:861-866, 1991.
151. R. Frydman, C. Cornel, D. de Ziegler, J. Taieb, I.M. Spitz, and P. Bouchard, Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin-releasing hormone antagonist (Nal-Glu) during the late follicular phase. *Human Reprod.* 7:930-933, 1992.
152. P. Bouchard, S. Dubourdieu, S. Hajri, E. Le Nestour, M.F. d'Acremont, I. Leroy, I.M. Spitz, R. Frydman, and B. Charbonnel, Perspectives of the use of GnRH antagonists in gynecology, In: *GnRH, GnRH Analogs, Gonadotropins*

and Gonadal Peptides. (P. Bouchard, A. Caraty, H.J.T. Coelingh Bennink, and S.N. Pavlou, eds.), Parthenon Publishing Group, London, UK, pp. 265-284, 1993.

153. S. Durbourdieu, E. Le Nestour, I.M. Spitz, B. Charbonnel, and P. Bouchard, The combination of gonadotropin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to reduce follicular maturation. *Human Reprod.* 8:2056-2060, 1993.

154. S.M. Grunberg, M.H. Weiss, I.M. Spitz, S. Zaretsky, O. Kletzky, and S. Groshen, Long-term treatment with the oral antiprogesterone agent mifepristone (RU 486), In: *Adjuvant Therapy of Cancer VII.* (S.E. Salmon, eds.), J.B. Lippincott Co., Philadelphia, pp. 55-62, 1993.

155. I.M. Spitz and C.W. Bardin, Clinical applications of the antiprogesterone RU 486. *Endocrinologist* 3:58-66, 1993.

156. I.M. Spitz and C.W. Bardin, Mifepristone (RU 486) - A modulator of progesterone and glucocorticoid action. *N. Engl. J. Med.* 329:404-412, 1993.

157. I.M. Spitz and C.W. Bardin, Clinical pharmacology of RU 486 - An antiprogesterone and antiglucocorticoid. *Contraception* 48:403-444, 1993.

158. I.M. Spitz, H.B. Croxatto, A.M. Salvatierra, and O. Heikinheimo, Response to intermittent RU 486 in normal women. *Fertil. Steril.* 59:971-975, 1993.

159. I.M. Spitz, O. Heikinheimo, and C.E. Wade, The divergent effect of RU 486 on adrenal function in the dog is related to differences in its pharmacokinetics. *Acta Endocrinol.* 128:459-465, 1993.

160. H.M. Beier and I.M. Spitz (editors), *Progesterone Antagonists in Reproductive Medicine and Oncology*, *Human Reprod.* 9, Suppl. 1, Oxford University Press, Cary, NC, 1994.

161. S. Dubourdieu, B. Charbonnel, M.-F. d'Acremont, S. Carreau, I.M. Spitz, and P. Bouchard, Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the preovulatory period: The luteinizing hormone surge requires secretion of GnRH. *J. Clin. Endocrinol. Metab.* 78:343-347, 1994.

162. I.M. Spitz, H.B. Croxatto, P. Lahteenmaki, O. Heikinheimo, and C.W. Bardin, Effect of mifepristone on inhibition of ovulation and induction of luteolysis. *Human Reprod.* 9 (Suppl. 1):69-76, 1994.

163. I.M. Spitz (associate editor), *Principles of Pharmacology.* (P. Munson, R. Mueller, and G. Breese, eds.), Chapman & Hall, New York, 1995.

164. I.M. Spitz, Gonadotropins, In: Principles of Pharmacology. (P. Munson, R. Mueller, and G. Breese, eds.), Chapman & Hall, New York, pp. 865-876, 1995.
165. I.M. Spitz, Antiprogestins, In: Principles of Pharmacology. (P. Munson, R. Mueller, and G. Breese, eds.), Chapman & Hall, New York, pp. 877-882, 1995.
166. I.M. Spitz and I. Agranat, Antiprogestins: Modulators in reproduction. *Chemistry & Industry* 3:89-92, 1995.
167. A. Robbins and I.M. Spitz, Mifepristone: Clinical pharmacology. *Clin. Obstet. Gynecol.* 39, 436-450, 1996.
168. I.M. Spitz, H.B. Croxatto, and A. Robbins, Antiprogestins: Mechanism of action and contraceptive potential. *Ann. Rev. Pharmacol. Toxicol.* 36:47-81, 1996.
169. I.M. Spitz and A. Robbins, The antiprogestins - modulators of progesterin and glucocorticoid function, In: Recent developments in Gynecology and Obstetrics. Edited by A.R. Genazzani, F. Petraglia, G. D'Ambrogio, A.D. Genazzani, P.G. Artini. The Parthenon Publishing Group, New York, London, pp. 93-97, 1996.
170. I.M. Spitz and A. Robbins, The contraceptive potential of the antiprogestin mifepristone, In: Recent developments in Gynecology and Obstetrics. Edited by A.R. Genazzani, F. Petraglia, G. D'Ambrogio, A.D. Genazzani, P.G. Artini. The Parthenon Publishing Group, New York, London, pp.99-102, 1996.
171. C.W. Bardin, A. Robbins, B.M. O'Connor, I.M. Spitz, Medical Abortion, In: Current Therapy in Endocrinology and Metabolism. Edited by C.W. Bardin. Mosby, New York, pp.305-311, 1997.
172. O. Heikinheimo, S. Ranta, S. Grunberg, P. Lahteenmaki and I.M. Spitz, Alterations in the pituitary-thyroid and pituitary-adrenal axes – Consequences of longterm mifepristone treatment. *Metabolism*, 46: 292-296, 1997.
173. I.M. Spitz, C.W. Bardin, L. Benton and A. Robbins, Early pregnancy termination with mifepristone and misoprostol in the United States. *New Eng. J. Med.*, 338:1241-1247, 1998.
174. I.M. Spitz and A. Robbins, Mechanism of action and clinical effects of antiprogestins on the non - pregnant uterus. *Human Reprod. Update* 4: 584-593,1998.



175. T. Maruo, T. Samoto, S. Yoshida, H. Matsuo, H. Nash, I.M. Spitz, and E. Johansson, Estradiol/progesterone releasing vaginal rings for hormone replacement therapy in postmenopausal women, 9<sup>th</sup> International Menopause Society, World Congress on the Menopause, Yokohama, Japan, Monduzzi Editore S.p.A., Bologna, Italy, 209-213, 1999.
176. I.M. Spitz, Antiprogestins: In: Encyclopedia of Reproduction, Volume 1 (E. Knobil and J.D. Neill, eds) pp 238-247, Academic Press, 1999.
177. I.M. Spitz and A. Robbins, Antiprogestins in Clinical Practice. In: Progesterone and Antiprogestins in Clinical Practice. (R. Sitruk-Ware and D.R. Mishell, Jr, eds.) pp 377-391, Marcel Dekker Inc, New York, Basel, 1999.
178. I.M. Spitz, B. Chertin, T. Lindenberg, A. Farkas, Long-acting gonadotrophin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer. *New Engl. J. Med.* 340, 1439, 1999.
179. M.D. Creinin and I.M. Spitz, Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. *Amer. J. Obstet. and Gynecol.* 181, 1419-1424, 1999.
180. B. Chertin, I.M. Spitz, T. Lindenberg, N. Algur, T. Zer, P. Kuzma, A J. Moo Young, R. Catane and A. Farkas, An implant releasing the gonadotropin hormone-releasing hormone agonist Histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. *J. Urology*, 163, 838-844, 2000.
181. S. Christin-Maitre, P. Bouchard and I.M. Spitz, Medical termination of pregnancy, *New Engl. J. Med.* 342, 946-956, 2000.
182. O. Heikinheimo, S. Ranta, S. Grunberg and I.M Spitz, Alterations in thyroid function, gonadotropins and sex steroids consequent to long term mifepristone administration, *Steroids*, 65, 831-836, 2000.
183. T. Maruo, J.B. Laoag-Fernandez, H. Matsuo, T. Samoto, O. Kurachi, S. Takeuchi, I. M. Spitz, P. Pakarinen, P. Lahteenmaki and E. Johansson, Effects of levonorgestrel-releasing intrauterine system on the endometrium and the relevance to the management of menorrhagia caused by uterine myoma and adenomyosis, in T. Maruo, D. Barlow, H. Mardon and S. Kennedy (eds.), *Cell and Molecular Biology of Endometrium in Health and Disease*. Osaka : Soeisha, pp. 193-207, 2000.
184. T. Maruo, H. Matsuo, T. Samoto, Y. Shimomura, O. Kurachi, Z. Gao, Y. Wang, I. M. Spitz, and E. Johansson, Effects of Progesterone on Uterine Leiomyoma Growth and Apoptosis, *Steroids*, 65, 585-592, 2000.
185. T. Maruo, T. Samoto, S. Yoshida, A. L. Hamada, H. Nash, I. M. Spitz and E. Johansson, Usefulness of Estradiol/Progesterone releasing vaginal rings

in long-term treatment of postmenopausal women, *Adv. Obstet. Gynecol.* 52, 266-271, 2000.

186. I.M. Spitz, Guest Editor: Progestins, Progesterone Receptor Modulators, and Progesterone Antagonists, *Steroids*, 65, 543-850, 2000.

187. I. M. Spitz, The Bible: Truth or Legend, Fact or Fantasy? *Steroids*, 65, 841-846, 2000.

188. I. M. Spitz and K. Chwalisz, Progesterone Receptor Modulators and Progesterone Antagonists in Women's Health, *Steroids*, 65, 807-816, 2000.

189. I.M. Spitz and H. J. T. Coelingh Bennink, Progesterone Receptor Modulators at the start of a New Millennium, *Steroids*, 65, 837-838, 2000.

190. I.M. Spitz, P.F.A. Van Look, and H.J.T. Coelingh Bennink, The use of Progesterone Antagonists and Progesterone Receptor Modulators in Contraception, *Steroids*, 65, 817-824, 2000.

191. T. Eldar-Geva, I.M. Spitz, N.P. Groome, E.J. Margalioth and R. Homburg, Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome, *Human Reprod*, 16, 2552-2556, 2001

192. R.S. Newfield, I.M. Spitz, C. Isacson and M.I. New, Long term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia, *Clin. Endocrin.* 54, 399-404, 2001.

193. I.M. Spitz, Clinical applications and adverse effects of progesterone receptor antagonists (PAs) and selective progesterone receptor modulators (SPRMs), In: *UpToDate*, Rose, BD (Ed), *UpToDate*, Wellesley, MA, 2001.

194. I.M. Spitz, Medical termination of Pregnancy, In: *UpToDate*, Rose, BD (Ed), *UpToDate*, Wellesley, MA, 2001.

195. T. Maruo, J.B. Laoag-Fernandez, P. Pakarinen, H. Murakoshi, I. M. Spitz and E. Johansson, Effects of the Levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. *Human Reprod*, 16, 2103-2108, 2001

196. V. R. Panz, B. I. Joffe, I. M. Spitz, T. Lindenberg, A. Farkas and M. Haffejee, Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. *Endocrine*, 15, 213-216, 2001.

197. P. N. Schlegel, P. Kuzma, J. Frick, A. Farkas, A. Gomahr, I. M. Spitz, B. Chertin, D. Mack, A. Jungwirth, P. King, H. Nash, C. W. Bardin and A. Moo-Young, Effective long-term androgen suppression in men with prostate cancer

using a hydrogel implant with the GnRH agonist histrelin, *Urology*, 58, 578-582, 2001.

198. T. Eldar-Geva, E. J. Margalioth, A. Ben-Chetrit, M. Gal, D. M. Robertson, D. L. Healy, Y. Z. Diamant and I. M. Spitz, Serum inhibin B levels measured early during FSH administration for IVF may be of value in predicting the number of oocytes to be retrieved in normal and low responders. *Hum Reprod*, 17, 2331-2337, 2002.

199. I. M. Spitz, Proven and potential clinical applications of Mifepristone (RU486). *Reviews in Endocrine and Metabolic Disorders*, 3, 267-276, 2002.

200. I. M. Spitz, Ovarian Steroids, Guest editor, *Reviews in Endocrine and Metabolic Disorders*, 3, 173-283, 2002

201. T. Maruo, J.B. Laoag-Fernandez, H. Matsuo, T. Samoto, O. Kurachi, S. Takeuchi, I.M. Spitz, P. Pakarinen, P. Lahteenmaki and E. Johansson, Effects of levonogestrel-releasing intrauterine system on the endometrium and the relevance to the management of menorrhagia caused by uterine myoma and adenomyosis, In: T. Maruo, D. Barlow, H. Marndon, and S. Kennedy (Ed), *Cell and Molecular Biology of Endometrium in Health and Disease*. Osaka: Soeisha, pp. 193-207.

202. J.B. Laoag-Fernandez, T. Maruo, P. Pakarinen, I.M. Spitz and E. Johansson, Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis, *Human Reprod*, 18, 694-699, 2003

203. R. Haimov-Kochman, H. Amsalem, A. Adoni, Y. Lavy and I. M. Spitz, Management of a perforated levonorgestrel-medicated intrauterine device- a pharmacokinetic study: case report. *Human Reprod*, 18, 1231-3, 2003.

204. L. Hamada, T. Maruo, T. Samoto, S. Yoshida, H. Nash, I.M. Spitz and E. Johansson, Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. *Gynecol Endocrinol* 17, 247-254, 2003.

205. R. Sitruk-Ware and I. M. Spitz, Pharmacological properties of mifepristone: toxicology and safety in animal and humans studies. *Contraception*, 68, 409-420, 2003.

206. I. M. Spitz, Progesterone antagonists and progesterone receptor modulators, *Expert Opin Investig Drugs*, 12, 1693-707, 2003.

207. I. M. Spitz and F. Petraglia (Editors). *Proceedings of the 2<sup>nd</sup> International Symposium on Progestins, Progesterone Receptor Modulators and Progesterone Antagonists*. *Steroids*, 68, 759-1124, 2003.

208. I. M. Spitz, Progesterone antagonists and progesterone receptor modulators: an overview, *Steroids*, 68, 981-93, 2003.
209. A. Ben-Chetrit, T. Eldar-Geva, T. Lindenberg, M. Farhat, S. Shimonovitz, D. Zacut, H. Gelber, R. Sitruk-Ware, I. M. Spitz, Mifepristone does not induce cervical softening in non-pregnant women, *Hum Reprod*, 19, 2372-6, 2004.
210. I. M. Spitz, C. Lieter, B. Chertin, A. Fridmans, D. Koulikov, T. Lindenberg, H. Gelber, P. Kuzma and A. Farkas, GnRH Superanalog Implants for Prostate Cancer, *International Proceedings from the 12<sup>th</sup> International Congress of Endocrinology*, Lisbon, Portugal, Aug 31- Sep 4, 389-395, 2004
211. Chabbert-Buffet, G. Meduri, P. Bouchard, I. M. Spitz, Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications, *Hum Reprod Update*, 11, 293-307, 2005.
212. T. Eldar-Geva, E. J. Margalioth, M. Gal, A. Ben-Chetrit, N. Algur, E. Zylber-Haran, B. Brooks, M. Huerta and I. M. Spitz, Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism, *Hum Reprod*, 20, 1814-9, 2005.
213. A. Fridmans, B. Chertin, D. Koulikov, T. Lindenberg, H. Gelber, C. Lieter, A. Farkas, I. M. Spitz, Reversibility of androgen deprivation therapy in patients with prostate cancer, *J Urol*, 173, 784-9, 2005.
214. I. M. Spitz, Preface - Progesterone receptor antagonists and selective progesterone receptor modulators (SPRMs), *Semin Reprod Med*, 23, 3-7, 2005.
215. A. Ben-Chitrit, D. Hochner-Celnikier, T. Lindenberg, D. Zacut, S. Shimonovitz, H. Gelber and I. M. Spitz, Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. *Isr Med Assoc J*, 7, 302-6, 2005.
216. H. Hirsch, D. Gillis, D. Strick, A. Farkas, B. Chertin, T. Lindenberg, H. Gelber and I. M. Spitz, The histrelin implant: A novel new approach to the treatment of central precocious puberty, *Pediatrics*, 116(6), e798-802, 2005.
217. I. M. Spitz, S. Grunberg, N. Chabbert-Buffet, T. Lindenberg, H. Gelber and R. Sitruk-Ware, The management of patients on long-term treatment with mifepristone, *Fertil Steril*, 84(6), 1719-26, 2005
218. I. M. Spitz, Clinical applications of progesterone receptor antagonists (PRAs) and selective progesterone receptor modulators (SPRMs), *The Endocrinologist*, 15, 391-400, 2005.

219. I. M. Spitz, Mifepristone for the medical termination of pregnancy. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2005.
220. I. M. Spitz, Clinical applications and adverse effects of progesterone antagonists (PAs) and selective progesterone receptor modulators (SPRMs)-Short term gynecological and obstetrical indications, In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2005.
221. I. M. Spitz, Progesterone receptor antagonists (PAs) and selective progesterone receptor modulators (SPRMs), In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2005.
222. I. M. Spitz, Progesterone receptor antagonist. *Current Opinion in Investigational Drugs.* 7:1472-4472, 2006.
223. S. M. Grunberg, M. H. Weiss, C. A. Russell, I. M. Spitz, J. Ahmadi, A. Sadun and R. Sitruk-Ware, Long-term Administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. *Cancer Investigation.* 24:727-733, 2006.
224. I. Spitz, Progesterone receptor antagonists and selective progesterone receptor modulators: proven and potential clinical applications. *Expert Review of Obstetrics & Gynecology.* 2:227-242, 2007.
225. D. Koulikov, A. Fridmans, B. Chertin, O. Shenfeld, A. Farkas and I. M. Spitz, Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male? *Journal of Urology.* 177, 2267-2271, 2007.
226. Irving M. Spitz, Progesterone Receptor Antagonists. In: *Nuclear Receptors as Drug Targets.* Edited by Eckhard Ottow and Hilmar Weinmann Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-31872-8.
227. I. M. Spitz, B. Chertin, A. Fridmans, A. Farkas, A. Belanger, H. Hartman and F. Labrie, Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. *Prostate Cancer and Prostatic Diseases,* 12, 100-103, 2009.
228. I. M. Spitz, Clinical utility of progesterone receptor modulators and their effect on the endometrium. *Current Opinion in Obstetrics and Gynecology,* 21, 318–324, 2009.
229. I. M. Spitz, R. D. Wiehle, A. van As. Progesterone Receptor Modulators in Endometriosis: A New Therapeutic Option. In *Textbook of Endometriosis,*

p225-234: J García Velasco and B. Rizk, Editors. Jaypee Brothers Medical Publishers Ltd, India; 2009.

230. T. Eldar-Geva, G. Liberty, B. Chertin, A. Fridmans, A. Farkas, EJ Margalioth and I. M. Spitz, Relationships between FSH, inhibin B, anti-Mullerian hormone and testosterone during long-term treatment with the GnRH-agonist Histrelin in patients with prostate cancer. *European Journal of Endocrinology*, 162, 177-181, 2010.

231. H.J. Hirsch, N. Lahlou, D. Gillis, D. Strich, B. Rosenberg-Hagen, B. Chertin, A. Farkas, H. Hartman, and I. M. Spitz, Free  $\alpha$ -Subunit (FAS) is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant, *J Clin Endocrinol and Metab*, 95, 2841-2844, 2010.